Suzanne M M Verstappen

List of Publications by Year
in descending order

141	3,421	136950	182427
papers	citations	32 h-index	51 g-index

144	144	144	4276
all docs	docs citations	times ranked	citing authors

#	Article	IF	Citations
1	Work disability remains a major problem in rheumatoid arthritis in the 2000s: data from 32 countries in the QUEST-RA Study. Arthritis Research and Therapy, 2010, 12, R42.	3.5	217
2	Anti-TNF therapies and pregnancy: outcome of 130 pregnancies in the British Society for Rheumatology Biologics Register. Annals of the Rheumatic Diseases, 2011, 70, 823-826.	0.9	154
3	The incidence of rheumatoid arthritis in the UK: comparisons using the 2010 ACR/EULAR classification criteria and the 1987 ACR classification criteria. Results from the Norfolk Arthritis Register. Annals of the Rheumatic Diseases, 2013, 72, 1315-1320.	0.9	116
4	Mortality Trends in Patients With Early Rheumatoid Arthritis Over 20 Years: Results From the Norfolk Arthritis Register. Arthritis Care and Research, 2014, 66, 1296-1301.	3.4	113
5	Biologic therapies and pregnancy: the story so far. Rheumatology, 2014, 53, 1377-1385.	1.9	99
6	In patients with early rheumatoid arthritis, the new ACR/EULAR definition of remission identifies patients with persistent absence of functional disability and suppression of ultrasonographic synovitis. Annals of the Rheumatic Diseases, 2013, 72, 245-249.	0.9	80
7	Using lifestyle factors to identify individuals at higher risk of inflammatory polyarthritis (results) Tj ETQq1 1 0.784314 rgBT /Overlock 10	0.9	75
8	The Prevalence of Individual Histopathologic Features Varies according to Autoantibody Status in Muscle Biopsies from Patients with Dermatomyositis. Journal of Rheumatology, 2015, 42, 1448-1454.	2.0	75
9	Working status in patients with rheumatoid arthritis, ankylosing spondylitis and psoriatic arthritis: results from the British Society for Rheumatology Biologics Register. Rheumatology, 2010, 49, 1570-1577.	1.9	73
10	Prediction of primary non-response to methotrexate therapy using demographic, clinical and psychosocial variables: results from the UK Rheumatoid Arthritis Medication Study (RAMS). Arthritis Research and Therapy, 2018, 20, 147.	3.5	73
11	Systematic review of the predictors of statin adherence for the primary prevention of cardiovascular disease. PLoS ONE, 2019, 14, e0201196.	2.5	72
12	2021 EULAR recommendations regarding lifestyle behaviours and work participation to prevent progression of rheumatic and musculoskeletal diseases. Annals of the Rheumatic Diseases, 2023, 82, 48-56.	0.9	71
13	Rheumatoid arthritis and work: The impact of rheumatoid arthritis on absenteeism and presenteeism. Best Practice and Research in Clinical Rheumatology, 2015, 29, 495-511.	3.3	67
14	Twentyâ€Year Outcome and Association Between Early Treatment and Mortality and Disability in an Inception Cohort of Patients With Rheumatoid Arthritis: Results From the Norfolk Arthritis Register. Arthritis and Rheumatology, 2017, 69, 1566-1575.	5.6	63
15	How common is remission in juvenile idiopathic arthritis: A systematic review. Seminars in Arthritis and Rheumatism, 2017, 47, 331-337.	3.4	60
16	Health Assessment Questionnaire disability progression in early rheumatoid arthritis: Systematic review and analysis of two inception cohorts. Seminars in Arthritis and Rheumatism, 2014, 44, 131-144.	3.4	59
17	Look Beyond the Disease Activity Score of 28 Joints (DAS28): Tender Points Influence the DAS28 in Patients with Rheumatoid Arthritis. Journal of Rheumatology, 2012, 39, 22-27.	2.0	53
18	Rheumatoid factor and anti-citrullinated protein antibody positivity, but not level, are associated with increased mortality in patients with rheumatoid arthritis: results from two large independent cohorts. Arthritis Research and Therapy, 2014, 16, 483.	3.5	51

#	Article	IF	Citations
19	Profiling of Gene Expression Biomarkers as a Classifier of Methotrexate Nonresponse in Patients With Rheumatoid Arthritis. Arthritis and Rheumatology, 2019, 71, 678-684.	5.6	50
20	The prospective association between psychological distress and disease activity in rheumatoid arthritis: a multilevel regression analysis. Annals of the Rheumatic Diseases, 2012, 71, 192-197.	0.9	47
21	Economic consequences and potential benefits. Best Practice and Research in Clinical Rheumatology, 2011, 25, 607-624.	3.3	45
22	Patterns of pain over time among children with juvenile idiopathic arthritis. Archives of Disease in Childhood, 2018, 103, 437-443.	1.9	45
23	Smoking is associated with the concurrent presence of multiple autoantibodies in rheumatoid arthritis rather than with anti-citrullinated protein antibodies per se: a multicenter cohort study. Arthritis Research and Therapy, 2016, 18, 285.	3.5	43
24	OMERACT Filter Evidence Supporting the Measurement of At-work Productivity Loss as an Outcome Measure in Rheumatology Research. Journal of Rheumatology, 2016, 43, 214-222.	2.0	42
25	How common is clinically inactive disease in a prospective cohort of patients with juvenile idiopathic arthritis? The importance of definition. Annals of the Rheumatic Diseases, 2017, 76, 1381-1388.	0.9	42
26	Genome-wide association study of response to methotrexate in early rheumatoid arthritis patients. Pharmacogenomics Journal, 2018, 18, 528-538.	2.0	42
27	Anticarbamylated protein antibodies are associated with long-term disability and increased disease activity in patients with early inflammatory arthritis: results from the Norfolk Arthritis Register. Annals of the Rheumatic Diseases, 2016, 75, 1139-1144.	0.9	41
28	Psychological factors predict adherence to methotrexate in rheumatoid arthritis; findings from a systematic review of rates, predictors and associations with patient-reported and clinical outcomes. RMD Open, 2016, 2, e000171.	3.8	40
29	Validity of a two-component imaging-derived disease activity score for improved assessment of synovitis in early rheumatoid arthritis. Rheumatology, 2019, 58, 1400-1409.	1.9	39
30	Worker Productivity Outcome Measures: OMERACT Filter Evidence and Agenda for Future Research. Journal of Rheumatology, 2014, 41, 165-176.	2.0	37
31	The Longitudinal Course of Fatigue in Rheumatoid Arthritis: Results from the Norfolk Arthritis Register. Journal of Rheumatology, 2015, 42, 2059-2065.	2.0	35
32	Effects of physical exercise and body weight on disease-specific outcomes of people with rheumatic and musculoskeletal diseases (RMDs): systematic reviews and meta-analyses informing the 2021 EULAR recommendations for lifestyle improvements in people with RMDs. RMD Open, 2022, 8, e002168.	3.8	35
33	Early remission is associated with improved survival in patients with inflammatory polyarthritis: results from the Norfolk Arthritis Register. Annals of the Rheumatic Diseases, 2014, 73, 1677-1682.	0.9	34
34	Smoking, alcohol consumption and disease-specific outcomes in rheumatic and musculoskeletal diseases (RMDs): systematic reviews informing the 2021 EULAR recommendations for lifestyle improvements in people with RMDs. RMD Open, 2022, 8, e002170.	3.8	32
35	N-terminal pro-brain-type natriuretic peptide (NT-pro-BNP) and mortality risk in early inflammatory polyarthritis: results from the Norfolk Arthritis Registry (NOAR). Annals of the Rheumatic Diseases, 2014, 73, 684-690.	0.9	31
36	Importance of Contextual Factors When Measuring Work Outcome in Ankylosing Spondylitis: A Systematic Review by the OMERACT Worker Productivity Group. Arthritis Care and Research, 2015, 67, 1316-1327.	3.4	31

#	Article	IF	Citations
37	Reduction of longâ€term disability in inflammatory polyarthritis by early and persistent suppression of joint inflammation: Results from the Norfolk Arthritis Register. Arthritis Care and Research, 2011, 63, 945-952.	3.4	30
38	The prevalence of co-morbidities and their impact on physical activity in people with inflammatory rheumatic diseases compared with the general population: results from the UK Biobank. Rheumatology, 2018, 57, 2172-2182.	1.9	30
39	Quantifying the hepatotoxic risk of alcohol consumption in patients with rheumatoid arthritis taking methotrexate. Annals of the Rheumatic Diseases, 2017, 76, 1509-1514.	0.9	29
40	Why Do Patients with Inflammatory Arthritis Often Score States â€œWorse than Deathâ€•on the EQ-5D? An Investigation of the EQ-5D Classification System. Value in Health, 2009, 12, 1026-1034.	0.3	28
41	Exploring the validity of estimating EQ-5D and SF-6D utility values from the health assessment questionnaire in patients with inflammatory arthritis. Health and Quality of Life Outcomes, 2010, 8, 21.	2.4	28
42	Predictors and outcomes of sustained, intermittent or never achieving remission in patients with recent onset inflammatory polyarthritis: results from the Norfolk Arthritis Register. Rheumatology, 2016, 55, 1601-1609.	1.9	28
43	Content validity of global measures for at-work productivity in patients with rheumatic diseases: an international qualitative study. Rheumatology, 2016, 55, 1364-1373.	1.9	28
44	Longâ€Term Outcomes Following Achievement of Clinically Inactive Disease in Juvenile Idiopathic Arthritis. Arthritis and Rheumatology, 2018, 70, 1519-1529.	5.6	28
45	Risk factors for oral methotrexate failure in patients with inflammatory polyarthritis: results from a UK prospective cohort study. Arthritis Research and Therapy, 2018, 20, 50.	3.5	28
46	Learned helplessness predicts functional disability, pain and fatigue in patients with recent-onset inflammatory polyarthritis. Rheumatology, 2013, 52, 1233-1238.	1.9	27
47	Has the Severity of Rheumatoid Arthritis at Presentation Diminished Over Time?. Journal of Rheumatology, 2014, 41, 1590-1599.	2.0	27
48	Seropositivity is associated with insulin resistance in patients with early inflammatory polyarthritis: results from the Norfolk Arthritis Register (NOAR): an observational study. Arthritis Research and Therapy, 2011, 13, R159.	3.5	26
49	Infection rates in patients from five rheumatoid arthritis (RA) registries: contextualising an RA clinical trial programme. RMD Open, 2017, 3, e000498.	3.8	25
50	What is the outcome of RA in 2011 and can we predict it?. Best Practice and Research in Clinical Rheumatology, 2011, 25, 485-496.	3.3	23
51	The Association Between Low Socioeconomic Status With High Physical Limitations and Low Illness Selfâ€Perception in Patients With Juvenile Idiopathic Arthritis: Results From the Childhood Arthritis Prospective Study. Arthritis Care and Research, 2015, 67, 382-389.	3.4	23
52	Have the 10-year outcomes of patients with early inflammatory arthritis improved in the new millennium compared with the decade before? Results from the Norfolk Arthritis Register. Annals of the Rheumatic Diseases, 2018, 77, annrheumdis-2017-212426.	0.9	23
53	Influence of age and sex on functional outcome over time in a cohort of patients with recentâ€onset inflammatory polyarthritis: Results from the Norfolk arthritis register. Arthritis Care and Research, 2011, 63, 1745-1752.	3.4	22
54	The impact of socio-economic status in rheumatoid arthritis. Rheumatology, 2016, 56, kew428.	1.9	22

#	Article	IF	Citations
55	The impact of lifestyle behaviours, physical activity and smoking on morbidity and mortality in patients with rheumatoid arthritis. Best Practice and Research in Clinical Rheumatology, 2020, 34, 101562.	3.3	20
56	Extensive variability of work participation outcomes measured in randomized controlled trials: a systematic review. Journal of Clinical Epidemiology, 2022, 142, 60-99.	5.0	20
57	Test-retest Reliability and Correlations of 5 Global Measures Addressing At-work Productivity Loss in Patients with Rheumatic Diseases. Journal of Rheumatology, 2016, 43, 433-439.	2.0	19
58	In patients with early inflammatory polyarthritis, ACPA positivity, younger age and inefficacy of the first non-biological DMARD are predictors for receiving biological therapy: results from the Norfolk Arthritis Register. Annals of the Rheumatic Diseases, 2011, 70, 1428-1432.	0.9	18
59	Methodological issues when measuring paid productivity loss in patients with arthritis using biologic therapies: an overview of the literature. Rheumatology, 2012, 51, 216-229.	1.9	18
60	How comparable are rates of malignancies in patients with rheumatoid arthritis across the world? A comparison of cancer rates, and means to optimise their comparability, in five RA registries. Annals of the Rheumatic Diseases, 2016, 75, 1789-1796.	0.9	18
61	Do we need bone mineral density to estimate osteoporotic fracture risk? A 10-year prospective multicentre validation study. RMD Open, 2017, 3, e000509.	3.8	18
62	Increased Frailty in Individuals With Osteoarthritis and Rheumatoid Arthritis and the Influence of Comorbidity: An Analysis of the UK Biobank Cohort. Arthritis Care and Research, 2022, 74, 1989-1996.	3.4	18
63	Predictors of presenteeism, absenteeism and job loss in patients commencing methotrexate or biologic therapy for rheumatoid arthritis. Rheumatology, 2020, 59, 2908-2919.	1.9	17
64	Prevalence and predictors of adverse events with methotrexate mono- and combination-therapy for rheumatoid arthritis: a systematic review. Rheumatology, 2021, 60, 4001-4017.	1.9	17
65	Methodological Challenges When Comparing Demographic and Clinical Characteristics of International Observational Registries. Arthritis Care and Research, 2015, 67, 1637-1645.	3.4	16
66	Can rheumatoid arthritis (RA) registries provide contextual safety data for modern RA clinical trials? The case for mortality and cardiovascular disease. Annals of the Rheumatic Diseases, 2016, 75, 1797-1805.	0.9	16
67	Scope of Outcomes in Trials and Observational Studies of Interventions Targeting Medication Adherence in Rheumatic Conditions: A Systematic Review. Journal of Rheumatology, 2020, 47, 1565-1574.	2.0	15
68	Comparative Genetic Analysis of Psoriatic Arthritis and Psoriasis for the Discovery of Genetic Risk Factors and Risk Prediction Modeling. Arthritis and Rheumatology, 2022, 74, 1535-1543.	5.6	15
69	Do associations between education and obesity vary depending on the measure of obesity used? A systematic literature review and meta-analysis. SSM - Population Health, 2021, 15, 100884.	2.7	14
70	Effect of anti-tumor necrosis factor on work disability. Journal of Rheumatology, 2007, 34, 2126-8.	2.0	14
71	Comparison of the risks of hospitalisation for cardiovascular events in patients with rheumatoid arthritis treated with tocilizumab and etanercept. Clinical and Experimental Rheumatology, 2018, 36, 310-313.	0.8	14
72	Outcomes of early rheumatoid arthritis â€“ The WHO ICF framework. Best Practice and Research in Clinical Rheumatology, 2013, 27, 555-570.	3.3	13

#	Article	IF	Citations
73	Development and validation of a methotrexate adherence assay. Annals of the Rheumatic Diseases, 2019, 78, 1192-1197.	0.9	13
74	Not all moderate disease is the same â€“ Identification of disability trajectories among patients with rheumatoid arthritis and moderate disease activity. PLoS ONE, 2019, 14, e0215999.	2.5	13
75	Considerations for Evaluating and Recommending Worker Productivity Outcome Measures: An Update from the OMERACT Worker Productivity Group. Journal of Rheumatology, 2019, 46, 1401-1405.	2.0	13
76	EULAR Points to Consider (PtC) for designing, analysing and reporting of studies with work participation as an outcome domain in patients with inflammatory arthritis. Annals of the Rheumatic Diseases, 2021, 80, 1116-1123.	0.9	13
77	Rates and predictors of methotrexate-related adverse events in patients with early rheumatoid arthritis: results from a nationwide UK study. Rheumatology, 2022, 61, 3930-3938.	1.9	13
78	Baseline patient reported outcomes are more consistent predictors of long-term functional disability than laboratory, imaging or joint count data in patients with early inflammatory arthritis: A systematic review. Seminars in Arthritis and Rheumatism, 2018, 48, 384-398.	3.4	12
79	Economic Theory and Self-Reported Measures of Presenteeism in Musculoskeletal Disease. Current Rheumatology Reports, 2016, 18, 53.	4.7	11
80	HLA-A 31:01 is not associated with the development of methotrexate pneumonitis in the UK population: results from a genome-wide association study. Annals of the Rheumatic Diseases, 2017, 76, e51-e51.	0.9	11
81	EULAR/eumusc.net standards of care for rheumatoid arthritis: cross-sectional analyses of importance, level of implementation and care gaps experienced by patients and rheumatologists across 35 European countries. Annals of the Rheumatic Diseases, 2020, 79, 1423-1431.	0.9	11
82	Changes in the illness perceptions of patients with rheumatoid arthritis over the first year of methotrexate therapy. Rheumatology, 2021, 60, 2355-2365.	1.9	11
83	The relation between cartilage biomarkers (C2C, C1,2C, CS846, and CPII) and the long-term outcome of rheumatoid arthritis patients within the CAMERA trial. Arthritis Research and Therapy, 2011, 13, R70.	3.5	10
84	Consensus Decision Models for Biologics in Rheumatoid and Psoriatic Arthritis: Recommendations of a Multidisciplinary Working Party. Rheumatology and Therapy, 2015, 2, 113-125.	2.3	10
85	Association of anti-carbamylated protein antibodies with long-term disability and increased disease activity in patients with early inflammatory arthritis: results from the Norfolk Arthritis Register. Lancet, The, 2015, 385, S44.	13.7	10
86	Predictors of and outcomes following orthopaedic joint surgery in patients with early rheumatoid arthritis followed for 20 years. Rheumatology, 2017, 56, 1510-1517.	1.9	10
87	The effect on work presenteeism of job retention vocational rehabilitation compared to a written self-help work advice pack for employed people with inflammatory arthritis: protocol for a multi-centre randomised controlled trial (the WORKWELL trial). BMC Musculoskeletal Disorders, 2020, 21, 607.	1.9	10
88	Conceptual model for the health technology assessment of current and novel interventions in rheumatoid arthritis. PLoS ONE, 2018, 13, e0205013.	2.5	9
89	Follow-up regimes for sick-listed employees: A comparison of nine north-western European countries. Health Policy, 2022, 126, 619-631.	3.0	9
90	Association of chemokine CXC ligand 12 gene polymorphism (rs1746048) with cardiovascular mortality in patients with rheumatoid arthritis: results from the Norfolk Arthritis Register: TableÂ1. Annals of the Rheumatic Diseases, 2015, 74, 2099-2102.	0.9	8

#	Article	IF	Citations
91	Long-term outcomes of patients who rate symptoms of rheumatoid arthritis as â€˜satisfactoryâ€™. Rheumatology, 2020, 59, 1853-1861.	1.9	8
92	Patients with rheumatoid arthritis facing sick leave or work disability meet varying regulations: a study among rheumatologists and patients from 44 European countries. Annals of the Rheumatic Diseases, 2019, 78, 1472-1479.	0.9	7
93	A Systematic Review of Productivity in Economic Evaluations of Workplace Interventions: A Need for Reporting Criteria?. Applied Health Economics and Health Policy, 2019, 17, 591-613.	2.1	7
94	OMERACT consensus-based operational definition of contextual factors in rheumatology clinical trials: A mixed methods study. Seminars in Arthritis and Rheumatism, 2021, 51, 601-606.	3.4	7
95	Preferred Methods of Measuring Work Participation: An International Survey Among Trialists and Cochrane Systematic Reviewers. Journal of Occupational Rehabilitation, 2022, 32, 620-628.	2.2	7
96	Prediction of Vertebral Fractures Is Specific for Gender and Site of Bone Mineral Density Measurement. Journal of Rheumatology, 2010, 37, 149-154.	2.0	6
97	Using epidemiological registry data to provide background rates as context for adverse events in a rheumatoid arthritis drug development program: a coordinated approach. Pharmacoepidemiology and Drug Safety, 2015, 24, 1121-1132.	1.9	6
98	Prediction of response and adverse events to methotrexate treatment in patients with rheumatoid arthritis. International Journal of Clinical Rheumatology, 2012, 7, 559-567.	0.3	5
99	Demographic and disease-related predictors of abnormal lung function in patients with established inflammatory polyarthritis and a comparison with the general population. Annals of the Rheumatic Diseases, 2013, 72, 1517-1523.	0.9	5
100	2010 ACR/EULAR classification criteria for rheumatoid arthritis predict increased mortality in patients with early arthritis: results from the Norfolk Arthritis Register. Rheumatology, 2013, 52, 1141-1142.	1.9	5
101	Direct Health Costs of Inflammatory Polyarthritis 10 Years after Disease Onset: Results from the Norfolk Arthritis Register. Journal of Rheumatology, 2015, 42, 794-798.	2.0	5
102	Do people with rheumatoid arthritis maintain their physical activity level at treatment onset over the first year of methotrexate therapy?. Rheumatology, 2021, 60, 4633-4642.	1.9	5
103	Exploring the disparity between inflammation and disability in the 10-year outcomes of people with rheumatoid arthritis. Rheumatology, 2022, 61, 4687-4701.	1.9	5
104	Epidemiology of rheumatic and musculoskeletal diseases. Best Practice and Research in Clinical Rheumatology, 2018, 32, 167-168.	3.3	4
105	Predicting presenteeism using measures of health status. Quality of Life Research, 2022, 31, 425-435.	3.1	4
106	The burden of musculoskeletal disease. Medicine, 2022, 50, 82-84.	0.4	4
107	Investigation of C reactive protein gene polymorphisms as predictors of cardiovascular mortality in inflammatory polyarthritis: results from the Norfolk Arthritis Register: TableÂ1. Annals of the Rheumatic Diseases, 2013, 72, 1429-1430.	0.9	3
108	Response to: Quantifying the hepatotoxic risk of alcohol consumption in patients with rheumatoid arthritis by Kremer and Weinblatt. Annals of the Rheumatic Diseases, 2018, 77, e5-e5.	0.9	3

#	Article	IF	Citations
109	Overview of changes in RMD epidemiology and outcome development in the last 10 years. Best Practice and Research in Clinical Rheumatology, 2018, 32, 169-173.	3.3	3
110	Pre-defined gene co-expression modules in rheumatoid arthritis transition towards molecular health following anti-TNF therapy. Rheumatology, 2022, 61, 4935-4944.	1.9	3
111	Methotrexate for Rheumatoid Arthritis: A Guide from Canada. Journal of Rheumatology, 2010, 37, 1374-1376.	2.0	2
112	Disease Activity, Smoking, and Reproductive-related Predictors of Poor Prognosis in Patients with Very Early Inflammatory Polyarthritis. Journal of Rheumatology, 2011, 38, 429-433.	2.0	2
113	Common Functional Ability Score for Young People With Juvenile Idiopathic Arthritis. Arthritis Care and Research, 2021, 73, 947-954.	3.4	2
114	How Do We Classify Rheumatoid Arthritis in Established Disease â€" Can We Apply the 2010 American College of Rheumatology/European League Against Rheumatism Classification Criteria?. Journal of Rheumatology, 2014, 41, 2347-2351.	2.0	1
115	153.â€ƒASSESSMENT OF PREDICTORS OF AND OUTCOMES FOLLOWING ORTHOPAEDIC JOINT SURGERY OVER 20 YEARS IN PATIENTS WITH EARLY RHEUMATOID ARTHRITIS RECRUITED TO THE NORFOLK ARTHRITIS REGISTER. Rheumatology, 2017, 56, .	1.9	1
116	Using qualitative methods for a conceptual analysis of measures of health status and presenteeism prior to a mapping study. Quality of Life Research, 2020, 29, 3167-3177.	3.1	1
117	O27â€ƒFrailty and co-morbidity in people with osteoarthritis and rheumatoid arthritis. Rheumatology, 2021, 60, .	1.9	1
118	O31â€ƒTrajectories of anxiety in children young people and adults with rheumatic diseases in the wake of COVID-19: results from the COVID-19 European patient registry. Rheumatology, 2021, 60, .	1.9	1
119	Researchersâ€™ perspectives on methodological challenges and outcomes selection in interventional studies targeting medication adherence in rheumatic diseases: an OMERACT-adherence study. BMC Rheumatology, 2021, 5, 26.	1.6	1
120	Ã‰tude et Suivi:Rheumatoid Arthritis in the 21st Century. Journal of Rheumatology, 2013, 40, 1637-1639.	2.0	0
121	035.â€ƒComprehensibility of Global Measures for at-Work Productivity in Patients with Rheumatic Conditions: An International Qualitative Study. Rheumatology, 0, , .	1.9	0
122	159.â€ƒTHE IMPORTANCE OF ACHIEVING CLINICAL RESPONSE TO TREATMENT AND CHANGES IN PHYSICAL ABILITY AND QUALITY OF LIFE ON WORKER PRODUCTIVITY OUTCOMES IN RHEUMATOID ARTHRITIS: RESULTS FROM THE BRITISH SOCIETY FOR RHEUMATOLOGY BIOLOGICS REGISTER FOR RHEUMATOID ARTHRITIS. Rheumatology, 2017, 56, .	1.9	0
123	Reply. Arthritis and Rheumatology, 2017, 69, 2402-2403.	5.6	0
124	O12â€ƒValidity of a2-component imaging-derived disease activity score (2C-DAS28) for improved assessment of synovitis in early rheumatoid arthritis. Rheumatology, 2018, 57, .	1.9	0
125	P41â€ƒA UK study: vocational experiences of young adults with juvenile idiopathic arthritis. Rheumatology, 2018, 57, .	1.9	0
126	227â€ƒPredictors of presenteeism and absenteeism in patients commencing treatment with methotrexate monotherapy or biologic therapy for rheumatoid arthritis. Rheumatology, 2018, 57, .	1.9	0

#	Article	IF	Citations
127	e11â€ƒPatterns of the patient acceptable symptom state over 12 months following the initiation of methotrexate therapy in patients with rheumatoid arthritis, and the association between these patterns and disability and disease activity. Rheumatology, 2018, 57, .	1.9	0
128	e51â€ƒExploring the impact of health status and capability of people with inflammatory arthritis on presenteeism in the workplace: a qualitative study. Rheumatology, 2018, 57, .	1.9	0
129	089â€ƒThe association between poor prognostic factors at methotrexate initiation and disease activity and disability over one year: results from the Rheumatoid Arthritis Medication Study. Rheumatology, 2018, 57, .	1.9	0
130	296â€ƒUK survey of young adults with juvenile idiopathic arthritis and their vocational experiences. Rheumatology, 2018, 57, .	1.9	0
131	e12â€ƒClinical phenotypes of patients with rheumatoid arthritis who identify as in a patient acceptable symptom state at methotrexate initiation and a comparison of the outcome of these phenotypes over 12 months. Rheumatology, 2018, 57, .	1.9	0
132	e10â€ƒModerate to good construct validity of global presenteeism measures with multi-item presenteeism measure and patient-reported health outcomes. Rheumatology, 2018, 57, .	1.9	0
133	085â€ƒWorker productivity loss remains a major issue for patients with inflammatory arthritis and osteoarthritis: results from an international worker-productivity study. Rheumatology, 2018, 57, .	1.9	0
134	O29â€ƒPredicting remission from one year following initial presentation in a multicentre inception cohort of patients with juvenile idiopathic arthritis. Rheumatology, 2018, 57, .	1.9	0
135	A UK study: vocational experiences of young adults with juvenile idiopathic arthritis. Pediatric Rheumatology, 2019, 17, 54.	2.1	0
136	FRI0674â€…THE ASSOCIATION BETWEEN JOINT EROSIONS PLUS AUTOANTIBODY POSITIVITY AT INITIATION OF METHOTREXATE OR BIOLOGIC THERAPY FOR RHEUMATOID ARTHRITIS AND DISEASE ACTIVITY AND DISABILITY OVER ONE YEAR. , 2019, , .		0
137	THU0668â€…THE ASSOCIATION BETWEEN ANTI-CCP TITRE LEVEL AND DISEASEACTIVITY AND DISABILITY OVER ONE YEAR FOLLOWING THE INITIATION OF METHOTREXATE OR BIOLOGIC THERAPY FOR ANTI-CCP+ RHEUMATOID ARTHRITIS. , 2019, , .		0
138	OP0265â€…FRAILTY, DISABILITY, AND WORK DISABILITY IN PEOPLE WITH OSTEOARTHRITIS AND RHEUMATOID ARTHRITIS. , 2019, , .		0
139	O06â€ƒBaseline predictors of methotrexate-related adverse events in methotrexate-naÃ¯ve patients with RA. Rheumatology, 2021, 60, .	1.9	0
140	P090â€ƒClinical prediction models for methotrexate treatment outcomes in rheumatoid arthritis patients: a review of existing models and summary of their limitations. Rheumatology, 2022, 61, .	1.9	0
141	OA28â€ƒExploring the potential of polygenic risk scores for predicting coronary artery disease in patients with rheumatoid arthritis. Rheumatology, 2022, 61, .	1.9	0